Betrixaban in the Prevention of Venous Thromboembolism in Medically Ill Patients

References

• Wendelboe AM , McCumberM, HylekEM, BullerH, WeitzJI, RaskobG . Global public awareness of venous thromboembolism . J. Thromb. Haemost.13 ( 8 ), 1365 – 1371 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kahn SR , LimW, DunnASet al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis (9th Ed.). American College of Chest Physicians Evidence-Based Clinical Practice Guidelines . Chest141 ( Suppl. 2 ), e195S – e226S ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Samama MM , CohenAT, DarmonJYet al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely Ill medical patients . N. Engl. J. Med.341, 793 – 800 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Ridker PM , GoldhaberSZ, DanielsonEet al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism . N. Engl. J. Med.348 ( 15 ), 1425 – 1434 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Cohen AT , DavidsonBL, GallusASet al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial . BMJ332, 325 – 329 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Amin AN , VarkerH, PrincicN, LinJ, ThompsonS, JohnstonS . Duration of venous thromboembolism risk across a continuum in medically Ill hospitalized patients . J. Hosp. Med.7, 231 – 238 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Heit JA , CrusanDJ, AshraniAA, PettersonTM, BaileyKR . Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US . Blood130 ( 2 ), 109 – 114 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Beckman MG , HooperWC, CritchleySE, OrtelTL . Venous thromboembolism A public health concern . Arch. Intern. Med.167 ( 14 ), 1471 – 1475 ( 2007 ).
   PubMedGoogle Scholar
• Hull RD , SchellongSM, TapsonVFet al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial . Ann. Intern. Med.153 ( 1 ), 8 – 18 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Cohen AT , SpiroTE, BullerHRet al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients . N. Engl. J. Med.368, 513 – 523 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ , LeizoroviczA, KakkarAKet al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients . N. Engl. J. Med.365, 2167 – 2177 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chi G , GoldhaberSZ, KittelsonJMet al. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis . J. Thromb. Haemost.15 ( 10 ), 1913 – 1922 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Raskob GE , SpyropoulosAC, ZrubekJet al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications . Thromb. Haemost.115 ( 6 ), 1240 – 1248 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Cohen AT , HarringtonRA, GoldhaberSZet al. Extended thromboprophylaxis with betrixaban in acutely Ill medical patients . N. Engl. J. Med.375, 534 – 544 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Bevyxxa (betrixaban) prescribing information . Portola Pharmaceuticals, Inc., South San Francisco, CA, USA ( 2017 ). www.bevyxxa.com/wp-content/uploads/2017/11/bevyxxa-betrixaban-capsules-prescribing-information-pdf.pdf .
   Google Scholar
• Zhang P , HuangW, WangLet al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor . Bioorg. Med. Chem. Lett.19 ( 8 ), 2179 – 2185 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sinha U , EdwardsST, WongPWet al. Antithrombotic activity of PRT54021, a potent oral direct factor Xa inhibitor, can be monitored using a novel prothrombinase inhibition bioassay . Blood108 ( 11 ), 907 ( 2006 ).
   Web of Science ®Google Scholar
• Abe K , SiuG, EdwardsSet al. Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral factor Xa inhibitor . Blood108 ( 11 ), 901 ( 2006 ).
   Web of Science ®Google Scholar
• Turpie AG , BauerKA, DavidsonBLet al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) . Thromb. Haemost.101 ( 1 ), 68 – 76 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chan NC , HirshJ, GinsbergJS, EikelboomJW . Betrixaban (PRT054021): pharmacology, dose selection and clinical studies . Future Cardiol.10 ( 1 ), 43 – 52 ( 2014 ).
   PubMedGoogle Scholar
• Chan NC , BhagirathV, EikelboomJW . Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism . Vasc. Health Risk Manag.11, 343 – 351 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Morganroth J , GretlerDD, HollenbachSJ, LambingJL, SinhaU . Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study . Expert Opin. Pharmacother.14 ( 1 ), 5 – 13 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Data on file . Portola Pharmaceuticals, Inc., South San Franciso, CA . MP-BET-US-0068 ( 2017 ).
   Google Scholar
• Connolly SJ , EikelboomJ, DorianPet al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a Phase 2, randomized, dose-ranging study (Explore-Xa) . Eur. Heart J.34 ( 20 ), 1498 – 1505 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cohen AT , HarringtonR, GoldhaberSZet al. The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study . Am. Heart J.167 ( 3 ), 335 – 341 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cohen AT , SpiroTE, SpyropoulosACet al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial . J. Thromb. Haemost.12 ( 4 ), 479 – 87 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gibson CM , GoldhaberSZ, CohenATet al. When academic research organizations and clinical research organization disagree: processes to minimize discrepancies prior to unblinding randomized trials . Am. Heart J.189, 1 – 8 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Gibson CM , HalabyR, KorjianSet al. The safety and efficacy of full- versus reduced-dose betrixaban in the acute medically Ill VTE (venous thromboembolism) prevention with extended-duration betrixaban (APEX) trial . Am. Heart J.185, 93 – 100 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Gibson CM , ChiG, HalabyRet al. Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically Ill patients an APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban) . Circulation135, 648 – 655 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Chi G , JanuzziJL, KorjianSet al. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy . J. Thromb. Thrombolysis44 ( 4 ), 457 – 465 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Gibson CM , NafeeT, YeeMKet al. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients . Am. Heart J.198, 84 – 90 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Chi G , YeeMK, AminANet al. Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely Ill hospitalized medical patients findings from the APEX trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial) . Circulation137, 91 – 94 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Yee MK , NafeeT, DaaboulYet al. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial . J. Thromb. Thrombolysis45 ( 1 ), 1 – 8 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Gibson CM , KorjianS, ChiGet al. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely Ill medical patients: an APEX trial substudy . J. Am. Heart Assoc.6, 1 – 5 ( 2017 ).
   Web of Science ®Google Scholar
• Chi G , GoldhaberSZ, HullRDet al. Thrombus burden of deep vein thrombosis and its association with thromboprophylaxis and D-dimer measurement: insights from the APEX trial . Thromb. Haemost.117 ( 12 ), 2389 – 2395 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Gibson CM , JenningsLK, ChiGet al. Association of D-dimer levels with clinical event rates and the efficacy of betrixaban versus enoxaparin in the APEX trial . TH Open.2 ( 1 ), e16 – e24 ( 2018 ).
   PubMedGoogle Scholar
• Conley PB , PineP, DeguzmanFet al. Andexanet alfa reduces betrixaban-induced blood loss in a rabbit liver laceration model of acute bleeding:P6208 . Eur. Heart J.38 ( Suppl. 1 ), 1320 ( 2017 ).
   Google Scholar
• Crowther M , LuG, LeedsJMet al. Reversal of betrixaban-induced anticoagulation in healthy volunteers by andexanet alfa . Blood128 ( 22 ), 143 ( 2016 ).
   Web of Science ®Google Scholar
• European Medicines Agency – Science Medicines Health . Refusal of the marketing authorisation for Dexxience (betrixaban) ( 2018 ). www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004309/WC500246331.pdf .
   Google Scholar